These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31292326)

  • 21. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
    Kotrych D; Dziedziejko V; Safranow K; Pawlik A
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population.
    Lv S; Fan H; Yang H; Huang J; Li J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Lv C; Kong X; Xiao C
    J Clin Pharmacol; 2019 Nov; 59(11):1471-1476. PubMed ID: 31099054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.
    Ranganathan P; Culverhouse R; Marsh S; Mody A; Scott-Horton TJ; Brasington R; Joseph A; Reddy V; Eisen S; McLeod HL
    J Rheumatol; 2008 Apr; 35(4):572-9. PubMed ID: 18381794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins.
    Soukup T; Nekvindova J; Dosedel M; Brtkova J; Toms J; Bastecka D; Bradna P; Vlcek J; Pavek P
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):790-795. PubMed ID: 27770044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
    Pawlik A; Dziedziejko V; Kurzawski M; Safranow K; Kotrych D; Bohatyrewicz A
    Pharmacol Rep; 2012; 64(1):185-90. PubMed ID: 22580535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.
    Soukup T; Dosedel M; Pavek P; Nekvindova J; Barvik I; Bubancova I; Bradna P; Kubena AA; Carazo AF; Veleta T; Vlcek J
    Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate.
    Prasad S; Tripathi D; Rai MK; Aggarwal S; Mittal B; Agarwal V
    Int J Rheum Dis; 2014 Nov; 17(8):878-86. PubMed ID: 24734954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.
    Hakamata J; Hashiguchi M; Kaneko Y; Yamaoka K; Shimizu M; Maruyama J; Takeuchi T; Mochizuki M
    Mod Rheumatol; 2018 Jul; 28(4):611-620. PubMed ID: 29252093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Qiu Q; Huang J; Shu X; Fan H; Zhou Y; Xiao C
    Sci Rep; 2017 Mar; 7():44015. PubMed ID: 28266606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis.
    Ghodke-Puranik Y; Puranik AS; Shintre P; Joshi K; Patwardhan B; Lamba J; Niewold TB; Chopra A
    Pharmacogenomics; 2015 Dec; 16(18):2019-34. PubMed ID: 26616421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia.
    Sha HX; Veerapen K; Chow SK; Gun SC; Lau IS; Lim RLH; Zulkifli Z; Yow YY; Peh SC; Hwang JS
    Sci Rep; 2022 Jul; 12(1):11844. PubMed ID: 35831345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.
    Majorczyk E; Pawlik A; Kuśnierczyk P
    Int Immunopharmacol; 2010 Dec; 10(12):1626-9. PubMed ID: 20888443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis.
    Hayashi H; Fujimaki C; Daimon T; Tsuboi S; Matsuyama T; Itoh K
    J Clin Pharm Ther; 2009 Jun; 34(3):355-61. PubMed ID: 19827168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenosine Deaminase Gene Polymorphism and Baseline Serum Level of Adenosine Deaminase as a Biomarker of Response to Methotrexate in Rheumatoid Arthritis.
    Gangadharan H; Singh A; Majumder S; Aggarwal A
    J Clin Rheumatol; 2021 Dec; 27(8):e609-e611. PubMed ID: 33044386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.
    Nomair AM; Abdelati A; Dwedar FI; Elnemr R; Kamel YN; Nomeir HM
    Clin Rheumatol; 2024 Mar; 43(3):971-983. PubMed ID: 38311638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism of genes involved in methotrexate pathway: Predictors of response to methotrexate therapy in Indian rheumatoid arthritis patients.
    Singh A; Gangadharan H; Gupta V; Patro PS; Misra R; Aggarwal A
    Int J Rheum Dis; 2021 May; 24(5):654-662. PubMed ID: 33780152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.